A porous microsphere for 3D cell culture and microtissue preparation and its application in transplantation therapy

By preparing porous microspheres, the problems of reduced stemness and low cell survival rate in 2D stem cell culture have been solved, providing efficient 3D cell culture and microtissue preparation, and achieving rapid cell proliferation and long-term therapeutic effects.

CN117567788BActive Publication Date: 2026-11-10SHENZHEN PEOPLES HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310902347.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-21
Publication Date
2026-11-10
Estimated Expiration
2043-07-21

AI Technical Summary

Technical Problem

Existing 2D stem cell culture methods result in reduced stemness, decreased chemotaxis, insufficient expansion rate, and low cell survival rate and short survival time during treatment, thus affecting the therapeutic effect.

Method used

A biodegradable porous microsphere is provided, which is formed by an oil-water emulsion crosslinking reaction of a biopolymer-mucopolysaccharide solution and an organic solution. The porous microsphere is used for 3D cell culture and micro-tissue preparation to simulate the in vivo microenvironment.

Benefits of technology

Porous microspheres provide high porosity and interconnected internal and external pores, increasing cell adhesion area and nutrient exchange efficiency, promoting cell proliferation and migration, enabling rapid cell proliferation and long-term culture, and slowly degrading and releasing cells in vivo to exert therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004352194290000011
    Figure HDA0004352194290000011
  • Figure HDA0004352194290000021
    Figure HDA0004352194290000021
  • Figure HDA0004352194290000022
    Figure HDA0004352194290000022
Patent Text Reader

Abstract

The application discloses a kind of porous microspheres for 3D cell culture and microtissue preparation and its application in transplantation therapy.The preparation of the porous microspheres of the application includes:1) preparing collagen-glycosaminoglycan solution as the aqueous phase, and organic solution containing emulsifier as the oil phase;2) adding the collagen-glycosaminoglycan solution dropwise into the organic solution containing emulsifier to obtain an oil-water mixed emulsion;3) carrying out crosslinking reaction of the oil-water mixed emulsion under the action of crosslinking agent to obtain a crosslinking reaction product containing solid collagen-glycosaminoglycan microspheres;4) sequentially freezing and freeze-drying the microspheres to obtain porous microspheres.The porous microspheres prepared by the application have high porosity, internal and external pore connectivity, and suitable pore size, and can obtain microtissue in a short time in a large scale in vitro.The microtissue can be epithelial tissue, connective tissue, muscle tissue or nerve tissue, and the preparation of microtissue can be used for transplantation therapy, and has wide application prospect in the field of regenerative medicine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of materials and cells in tissue engineering, and provides a porous microsphere for 3D cell culture and microtissue preparation and its application in transplantation therapy. Background Technology

[0002] With the development of regenerative medicine, cell therapy based on pluripotent cells has provided new treatment options for intractable or rare diseases that are difficult to treat with current surgery or drugs. Stem cell therapy has become a research hotspot in regenerative medicine. The stem cells used in stem cell therapy include human pluripotent stem cells (hPSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). Numerous clinical studies have verified the safety and efficacy of MSCs in treating neurodegenerative diseases, cardiovascular diseases, graft-versus-host disease, wound repair, and tumors. However, most MSC treatments that have entered clinical trials have failed to achieve the main expected results. The clinical application of MSCs is mainly based on their immunomodulatory, tissue repair, homing, and paracrine properties.

[0003] Factors influencing the therapeutic efficacy of MSCs mainly include their homing characteristics, which enable them to migrate to damaged tissues to achieve therapeutic effects. However, multiple factors affect MSC homing, including MSC quality, transplantation time and quantity, culture method, transplantation carrier, and route of administration. A commonly used MSC culture method is 2D adherent culture. With increasing culture passages, this method gradually leads to a decrease in MSC stemness, resulting in reduced immunosuppressive and regenerative capabilities, as well as decreased chemotaxis, thus affecting therapeutic efficacy. After MSC transplantation, with prolonged transplantation time, changes in the microenvironment cause the death of a large number of transplanted cells, which are then phagocytosed by macrophages, significantly reducing the number of MSCs capable of therapeutic effects and thus lowering the therapeutic efficacy. In addition, the type of biomaterial carrier used during MSC transplantation and the route of administration are also important factors affecting the therapeutic efficacy of MSCs after transplantation.

[0004] In conclusion, to improve the therapeutic effect of MSCs on diseases, it is necessary to explore a culture method that can enhance MSC cell therapy, maintain the chemotaxis of cells, reduce MSC damage caused by drug administration, and maintain the MSC growth microenvironment to ensure that MSCs maintain an effective cell count and exert their efficacy after transplantation into the body.

[0005] Furthermore, tissue cells, including epithelial tissue, connective tissue, muscle tissue, and nerve tissue, still face challenges in cell regeneration therapy after injury, including low homing cell numbers, low in vivo cell survival rates, short cell survival times, and difficulty in achieving therapeutic effects. Therefore, the preparation of biodegradable 3D cell culture materials and micro-tissue materials that form with cultured cells has become a research direction. Summary of the Invention

[0006] Based on the above background, the main purpose of this invention is to address the problems in current 2D stem cell culture, such as reduced stemness, decreased chemotaxis, insufficient expansion rate, and low survival rate and short survival time of transplanted cells during treatment, which make it difficult to exert biological efficacy due to long-term culture. The invention provides a biodegradable porous microsphere for 3D cell culture and a method for forming micro-tissues with cultured cells.

[0007] In a first aspect, the present invention provides a method for preparing porous microspheres, comprising the following steps:

[0008] 1) Prepare a biological macromolecule-mucopolysaccharide solution as the aqueous phase and an organic solution containing an emulsifier as the oil phase;

[0009] The biopolymer-mucopolysaccharide solution is prepared by the following method: the mucopolysaccharide solution is added dropwise to the biopolymer solution and mixed well to obtain the biopolymer-mucopolysaccharide solution; wherein, the addition is carried out at a mass ratio of 5-11:1 between the biopolymer and the mucopolysaccharide.

[0010] In the above text, the solvent for both the biopolymer solution and the mucopolysaccharide solution is an aqueous acetic acid solution;

[0011] Specifically, the biopolymer-mucopolysaccharide solution is prepared according to the following method:

[0012] 1)-a. Dissolve the biopolymer and the mucopolysaccharide separately in an aqueous acetic acid solution to obtain a biopolymer solution and a mucopolysaccharide solution;

[0013] 1)-b. The mucopolysaccharide solution is added dropwise to the biopolymer solution to obtain a biopolymer-mucopolysaccharide solution;

[0014] The dripping is performed according to a mass ratio of 5-11:1 for the added biopolymer and the mucopolysaccharide.

[0015] In the above embodiments of the present invention, the biopolymer and the mucopolysaccharide are added in a mass ratio of 11:1 during dripping.

[0016] The organic solution containing the emulsifier is obtained by stirring and mixing the emulsifier with an organic solvent.

[0017] 2) The biopolymer-mucopolysaccharide solution is added dropwise to the organic solution containing the emulsifier, and the mixture is stirred until homogeneous to obtain an oil-water emulsion;

[0018] 3) The oil-water emulsion is subjected to a crosslinking reaction under the action of a crosslinking agent to obtain a crosslinking reaction product containing solid microspheres;

[0019] 4) The microspheres in the cross-linking reaction product containing solid microspheres are sequentially frozen and freeze-dried to form a microsphere porous structure, thereby obtaining porous microspheres.

[0020] In the method described above, the biopolymer is composed of one or more of collagen, alginate, polylactic acid, polyvinyl alcohol, chitosan and their degradation products. In the embodiments of the present invention, it is specifically type I porcine skin collagen with a molecular weight of 2000-300,000 kDa; the collagen solution contains 1% (g:ml) of collagen by mass and volume.

[0021] Alternatively, the mucopolysaccharide may be composed of one or more of keratin sulfate, chondroitin sulfate, hyaluronic acid, and dermatan sulfate, and in the embodiments of the present invention, it is specifically chondroitin sulfate; the chondroitin sulfate solution has a mass-volume percentage of chondroitin sulfate of 1.15% (g:ml).

[0022] In the method described above, the concentration of collagen in the collagen-mucopolysaccharide solution is 0.5%-5% (mass-volume percentage, g:ml);

[0023] Furthermore, the collagen concentration in the collagen-mucopolysaccharide solution is 0.8%-1.5%; even further, the collagen concentration in the collagen-mucopolysaccharide solution is specifically 1%. This concentration results in a collagen-mucopolysaccharide solution with appropriate viscosity, which can improve the mechanical strength and elasticity of the subsequently prepared microspheres, making them less prone to deformation or breakage during research and clinical operations, and thus providing greater operability. Therefore, a collagen-mucopolysaccharide concentration of 1% is adopted.

[0024] In the method described above, the organic solvent is one or more of petroleum ether, turpentine, liquid paraffin, and n-heptane; specifically, in the embodiments of the present invention, it is liquid paraffin.

[0025] Alternatively, the emulsifier may be a Tween surfactant, or a mixture of Span and Tween surfactants;

[0026] Further, the emulsifier is one or more of Tween 80, Span 80, Tween 20, whey protein, or sucrose fatty acid ester; specifically, in the embodiments of the present invention, it is Tween-20;

[0027] Alternatively, the volume percentage of the emulsifier in the organic solution containing the emulsifier is 0.5%-5%, and in the embodiments of the present invention, the specific volume percentage is 1%.

[0028] In the methods described above, the stirring speed is 50-2000 rpm.

[0029] Furthermore, the stirring speed is 500-600 rpm.

[0030] Furthermore, the preferred stirring speed is 500 rpm. Too high a speed can easily cause the microspheres to break, while too low a speed will cause the microspheres to settle, aggregate, and stick together. Therefore, the optimal stirring speed is selected as 500 rpm.

[0031] Alternatively, the mixing time is 30 minutes. If the mixing time is less than 30 minutes, the surface strength of the microspheres will be insufficient and they will be easily broken. If the mixing time is too long, the surface of the microspheres will be under continuous stress for a long time, which will affect the formation of microsphere pores. Therefore, the optimal time is selected as 30 minutes.

[0032] Alternatively, the mixing temperature is room temperature.

[0033] In the method described above, the collagen-mucopolysaccharide solution is added dropwise to the organic solution containing the emulsifier using a syringe needle with an inner diameter of 20-34G.

[0034] Furthermore, the inner diameter of the syringe needle is 27-30G.

[0035] Alternatively, the crosslinking agent is one or more of EDTA, glutaraldehyde, and acetic anhydride;

[0036] Furthermore, the crosslinking agent is EDTA.

[0037] In the above text, the crosslinking time is 5-60 min;

[0038] Alternatively, the amount of crosslinking agent added is 200-800mg of EDTA per 50mg of collagen;

[0039] Furthermore, in an embodiment of the present invention, the amount of crosslinking agent added is 400mg EDTA per 50mg collagen.

[0040] The cross-linking time mentioned above is 30 minutes.

[0041] In the method described above, the freezing conditions are 0-200°C, and further, the freezing conditions are -10-80°C, and the freezing time is 1-48 hours.

[0042] Furthermore, the freezing conditions are -23°C and the freezing time is 4 hours.

[0043] The freeze-drying process is vacuum freeze-drying, with a freezing temperature of -52℃ and a vacuum degree of 0.2mbar.

[0044] In the method described above, the concentration of the acetic acid solution is 0.01-0.5M.

[0045] Furthermore, in the embodiments of the present invention, the concentration of the acetic acid solution is specifically 0.05M;

[0046] Alternatively, between steps 3) and 4), the method may include collecting the solid microspheres by separating the oil phase of the crosslinking reaction product containing solid microspheres with ethanol, and collecting the microspheres by passing the collected solid microspheres through a 40-mesh sieve.

[0047] Furthermore, the concentration of the ethanol-water solution is 30%-100%;

[0048] The concentration of the ethanol aqueous solution is 50-75%, and in the embodiments of the present invention, a 75% ethanol aqueous solution is used.

[0049] Steps 1)-3) in the method described above are performed at room temperature.

[0050] In a second aspect, the present invention provides porous microspheres prepared by the method described in the first aspect.

[0051] The porous microspheres described above possess at least one of the following properties:

[0052] A1) In vivo biodegradability; the microsphere diameter range is adjustable, and the in vivo degradation rate can be controlled according to requirements.

[0053] A2) The inner and outer pores are connected; moreover, the outer pores are small, and the inner pores are large. Figure 2 (b can be shown) The small external pores can maximize the cell adhesion area, while the large internal pores can improve the exchange of nutrients and the excretion of harmful metabolic products by cells inside the microspheres. The interconnected structure of internal and external pores provides a pathway for cells to migrate into the microspheres.

[0054] A3) The diameter is 100-1500 μm and the pore size is 8-100 μm; further, the diameter of the porous microsphere is specifically 500-650 μm and the pore size is 20-60 μm;

[0055] A4) Injectability: The porous microspheres, or the cells released by enzymes after cell inoculation, can be directly injected into wounds or other sites requiring treatment. This injectability improves the ease and operability of its application.

[0056] Thirdly, the present invention provides the application of the porous microspheres described in the second aspect in any of the following:

[0057] B1) Cells can be cultured, expanded, migrated, or differentiated in vitro using 3D technology. The 3D spatial structure of the cells simulates the microenvironment in vivo, allowing the expanded culture and in vivo transplantation of cells to proliferate and differentiate as closely as possible to the state of cells in the human body. The porous and interconnected pore structure increases the adhesion area and pathway for cell proliferation and migration.

[0058] B2) Preparation of cellular microtissues; the aforementioned cellular microtissues are obtained by seeding cells onto the porous microspheres and then culturing them in vitro in a 3D manner. These cellular microtissues can be epithelial tissue, connective tissue, muscle tissue, or nerve tissue, etc.

[0059] B3) Preparation of transplant therapy products;

[0060] B4) To prepare small molecule substances or sustained-release products in cells, high water absorption (lyophilization forms pores, and then during 3D culture, it can have relatively strong water absorption) can increase the drug loading capacity, and at the same time, its selectable diameter range can control the release of the drug to the target.

[0061] The small molecule substances mentioned above are small molecule drugs;

[0062] The cells mentioned above are cultured animal or human cells. Specific examples include human or animal progenitor cells, stem cells, epidermal cell lines, fibroblasts, cancer cells, and other cell types that can be cultured adherently.

[0063] In embodiments of the present invention, the mesenchymal stem cells and dermal fibroblasts can proliferate, migrate, and distribute uniformly on the surface and pores of the microspheres. The epidermal cells can form an epidermal-like structure on the surface of the microspheres.

[0064] Fourthly, the present invention provides a cell microtissue, which is obtained by seeding cells on the porous microspheres described in the second aspect for in vitro 3D culture.

[0065] The aforementioned cellular micro-tissue is based on biodegradable porous microspheres, which can provide a suitable microenvironment for various tissue cells (such as epithelial cells, connective tissue cells, muscle cells, and nerve cells), protecting the cells so that they can survive in large numbers even after reaching the lesion. As the material degrades, the cells are slowly released to the lesion to continue to exert a therapeutic effect.

[0066] The 3D culture mentioned above refers to 3D dynamic culture; specifically, the porous microspheres described in the second aspect are first soaked in cell culture medium to allow the microspheres to fully absorb the culture medium, then cells are inoculated onto the microspheres that have absorbed the culture medium, and then placed in a bioreactor for 3D dynamic culture, wherein the rotation speed of the bioreactor is 45 rpm / min, and the culture conditions are 37℃ and 5% CO2 incubator.

[0067] Fifthly, the present invention provides the application of the cellular microtissues described in the fourth aspect in the preparation of transplantation therapy products.

[0068] In the above text, the transplantation treatment product is an injectable product or a topical product;

[0069] Furthermore, the transplantation treatment product is a product used to treat diseases caused by wound damage, diseases caused by joint damage, diseases caused by endometritis, or for cosmetic surgery, etc.

[0070] In the above text, the cells mentioned are cultured animal or human cells.

[0071] Furthermore, the cells are all cultured animal or human cells, such as stem cells, somatic cells, or cancer cells;

[0072] In embodiments of the present invention, further examples are given as follows: the stem cells are mesenchymal stem cells; the somatic cells are epidermal cells or fibroblasts.

[0073] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0074] 1) The porous microspheres provided by this invention have a regular spherical shape, good uniformity, and an adjustable diameter range. They possess high strength, elasticity, mechanical properties, and water absorption, with a large specific surface area, increasing the cell attachment area. They also have high porosity, and the internal and external pores are interconnected, providing pathways for cell migration into the microspheres and improving the exchange efficiency of cellular nutrients and metabolites. These characteristics provide favorable conditions for the formation of microtissues through in vitro 3D cell culture.

[0075] 2) The present invention further seedes epidermal cells and dermal fibroblasts on the surface of porous microspheres, wherein the epidermal cells form a single-cell layer or cell multilayer epidermal structure on the surface of the microspheres, and the fibroblasts are evenly distributed on the surface and inside of the microspheres to form a structure similar to the dermal layer of skin. The microspheres can provide material support for the culture of micro-tissues in vitro to simulate tissues and organs in vivo.

[0076] 3) The porous microspheres provided in this invention have good biocompatibility. Microtissues obtained by in vitro culture can rapidly proliferate and migrate on and inside the porous microspheres. The cells have high activity, rapid proliferation, and can be cultured for a long time.

[0077] 4) The porous microspheres provided in this invention have good biodegradability. They do not degrade during 3D cell culture and can be degraded enzymatically to release cells after culture. After transplantation into the body, the porous microspheres will slowly degrade and release cells through enzymatic hydrolysis in vivo due to the presence of enzymes released by the cells in the body fluids, thus exerting a therapeutic effect. The diameter of the microspheres is controllable, allowing for artificial control of the degradation rate in vivo, achieving effective controlled release of small molecules and therapeutic effects on micro-tissues.

[0078] In summary, the porous microsphere preparation method employed in this invention is simple, requires minimal operator skill, allows for controllable diameter control leading to a controllable degradation rate, and offers advantages such as good shape and uniformity, strong mechanical properties and elasticity making it resistant to breakage, and high swelling rate. The prepared porous microspheres possess high porosity, interconnected internal and external pores, and suitable pore size, providing a spatial structure for stem cell proliferation and migration, enabling large-scale 3D culture and expansion of stem cells in vitro to obtain microtissues. This method for preparing microtissues through in vitro 3D culture of porous microspheres offers advantages such as simple operation, rapid cell proliferation, and simulation of the in vivo microenvironment. After transplantation into the body, the microtissues, containing enzymes released by the cells in the body fluids, will slowly degrade and release cells to exert a therapeutic effect. Furthermore, its high operability and multiple drug delivery routes offer broad application prospects in the field of regenerative medicine. Attached Figure Description

[0079] Figure 1 The results are for collagen-mucopolysaccharide solutions, where a represents the collagen-mucopolysaccharide solution; b represents the results of solid microspheres prepared at different stirring speeds; c represents the diameter of solid microspheres prepared with collagen solutions of different concentrations; d is a statistical graph of the diameter of solid microspheres prepared with collagen solutions of different concentrations; and e represents the results of solid microspheres obtained with different injection needles.

[0080] Figure 2 The images show the characterization of porous microspheres; where a is a scanning electron microscope (SEM) image of porous microspheres prepared under different freezing conditions (scale bar: 100 μm), b is a scanning electron microscope image of a single porous microsphere, and c is a magnified view of a local area of ​​the porous microsphere surface.

[0081] Figure 3 Figure 1 shows microscopic images of MSCs and porous microspheres after 3D in vitro culture for 2-5 days. Figure 2a is a fluorescence inverted microscope image of a single micro-tissue, Figure 3b is an immunofluorescence staining image of cell distribution (left) and a Masson staining image (right), and Figure 4c is a crystal violet staining image.

[0082] Figure 4Microscopic images of epidermal cell lines and fibroblast cell lines cultured in porous microspheres for different time periods in vitro. Among them, a is the immunofluorescence image of epidermal cells cultured in microspheres for 10 days, b is the immunofluorescence image of a cross section of tissue slices of epidermal cells cultured in microspheres for 10 days, and c is the immunofluorescence image of fibroblasts cultured in porous microspheres for 2 days in vitro.

[0083] Figure 5 The images show microscopic images of cell lines and gelatin microspheres cultured for different time periods. a) shows the direct microscopic detection results of MSCs, b) shows the microscopic detection results of HaCaT cells, and c) shows the microscopic detection results of 3T3 cells after culturing in gelatin microspheres and staining the cell nuclei with DAPI staining solution.

[0084] Figure 6 The results show the effects of micro-tissue promoting wound repair. a) is a diagram of the construction of the full-skin injury model on the back; b) is the HE staining result of micro-tissue promoting wound repair; c) is the IF staining result of micro-tissue promoting wound repair. Detailed Implementation

[0085] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0086] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0087] To facilitate understanding of the present invention, the present invention will be described more fully and in more detail below with reference to the embodiments, but the scope of protection of the present invention is not limited to the specific embodiments.

[0088] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by those skilled in the art. The technical terms used herein are for the purpose of describing particular embodiments only and are not intended to limit the scope of the invention.

[0089] Unless otherwise stated, all raw materials, reagents, instruments and equipment used in this invention can be purchased from the market or prepared by existing methods.

[0090] Example 1: Preparation of porous microspheres for in vitro microtissue culture

[0091] I. Preparation of porous microspheres

[0092] 1. Preparation of aqueous collagen-mucopolysaccharide solution

[0093] 0.25g of type I porcine skin collagen (Sichuan Kele Co., Ltd.) was dissolved in 23ml of 0.05M glacial acetic acid aqueous solution to obtain a collagen solution (collagen mass-volume percentage 1%, g:ml); the above collagen solution was homogenized using a homogenizer at a stirring speed of 14000rpm / min for 30min (until no obvious particles were visible).

[0094] Dissolve 0.023 g of chondroitin sulfate (mucopolysaccharide) in 2 ml of 0.05 M acetic acid aqueous solution to obtain chondroitin sulfate solution (mucopolysaccharide mass-volume percentage of 1.15%).

[0095] Then, slowly add the above chondroitin sulfate solution dropwise to the collagen solution after stirring for 30 minutes, according to a collagen to mucopolysaccharide mass ratio of 11:1 (Note: the chondroitin sulfate solution should be added below the surface of the collagen solution during the dropwise addition process). Continue stirring for 2 hours (until the solution becomes a transparent gel). Centrifuge at 3500 rpm / min at 4°C for 30 minutes to eliminate air bubbles, and obtain the collagen-mucopolysaccharide solution (e.g., ...). Figure 1 As shown in Figure a, the collagen content in the solution is 1% by mass (volume percentage), and the solution is used as the aqueous phase (W).

[0096] 2. Preparation of oil phase emulsion

[0097] An organic solvent that is insoluble in water is selected as the oil phase (O). In the embodiments of the present invention, the oil phase is liquid paraffin.

[0098] Liquid paraffin containing emulsifier: Place 100ml of liquid paraffin in a 200ml beaker, add Tween-20 (emulsifier) ​​to make the final concentration 1% (volume percentage), adjust the mechanical stirring speed to 500rpm (stirring paddle diameter 50mm), stir for 30min to obtain liquid paraffin containing emulsifier with a volume percentage of 1%.

[0099] 3. Oil-water emulsions containing spherical droplets

[0100] Add 5 ml of the collagen-mucopolysaccharide solution obtained in step 1 (1% by volume) dropwise to 100 ml of the liquid paraffin containing emulsifier obtained in step 2 using a 30G syringe needle. The collagen-mucopolysaccharide solution forms spherical droplets with a diameter of about 500-650 μm in the oil phase. Continue mechanical stirring at 500 rpm at room temperature for 30 min to form an oil-water emulsion (W / O).

[0101] 4. Chemical cross-linking reaction

[0102] Add 2 ml of EDTA aqueous solution with a mass-volume percentage (g:ml) of 0.2% (400 mg of crosslinking agent EDTA dissolved in 2 ml of sterile ddH2O) to the 105 ml oil-water mixed emulsion obtained in step 3 above, and carry out a chemical crosslinking reaction at room temperature for 30 min to obtain the crosslinking reaction product containing solid microspheres.

[0103] The above-mentioned EDTA addition amount is 400mg EDTA per 50mg collagen.

[0104] 5. Preparation of porous microspheres

[0105] The pores are created by freezing the aqueous phase inside solid microspheres at low temperature, followed by vacuum freeze-drying to directly sublimate the ice crystals inside the spheres. This sublimation of the ice crystals creates a porous structure, as detailed below:

[0106] 1) Remove the oil phase

[0107] Add 50 ml of 75% ethanol aqueous solution to 107 ml of cross-linking reaction product obtained in step 4 (derived from 5 ml of collagen-mucopolysaccharide solution with a collagen mass-volume percentage of 1%) and continue stirring for 10 min; pour the above solution into a 50 ml centrifuge tube, centrifuge at 1500 rpm / min for 10 min, and collect the solid microspheres that have accumulated at the bottom of the centrifuge tube.

[0108] The solid microspheres were washed three times with 75% ethanol solution and then resuspended in ddH2O to obtain a solid microsphere solution.

[0109] 2) Freezing

[0110] The solid microsphere solution obtained in step 1) above was sieved through a 40-mesh sieve (for the purpose of collecting microspheres). The sieve containing the microspheres was then frozen in a -23°C freezer for 4 hours to obtain frozen microspheres.

[0111] 3) Freeze-drying

[0112] The frozen microspheres obtained in step 2) along with the mesh screen were placed in an ice box and quickly placed into a pre-cooled vacuum freeze dryer for vacuum freeze drying for 24 hours to form a microsphere porous structure. The vacuum freezing temperature was -52℃ and the vacuum degree was 0.2mbar, resulting in porous microspheres (collagen-GAG microspheres (CMS)).

[0113] II. Preparation methods of porous microspheres

[0114] 1. Exploring the stirring speed

[0115] Porous microspheres were prepared according to the method described above, except that mechanical stirring speeds of 500 rpm and 600 rpm were used in steps 2 and 3, respectively.

[0116] Solid microspheres prepared at different stirring speeds (before freezing) were observed and photographed using an optical microscope, and their diameters were measured using the instrument's built-in length measuring tool.

[0117] The results are as follows Figure 1 As shown in b, it can be seen that microspheres with intact structures were prepared by mechanical stirring at 500 rpm and freeze-drying, while the microspheres broke at 600 rpm.

[0118] 2. Concentration of collagen in collagen-mucopolysaccharide solution

[0119] Porous microspheres were prepared according to the method described above, except that collagen-mucopolysaccharide solutions with different collagen concentrations of 0.8%, 1%, and 1.5% were prepared in step 1.

[0120] Solid microspheres prepared from collagen-mucopolysaccharide solutions of different collagen concentrations (before freezing) were photographed after being dissolved in water. Figure 1 As shown in Figure c, the left figure represents 0.8% CMS, the middle figure represents 1% CMS, and the right figure represents 1.5% CMS; the diameter of the solid microspheres is statistically analyzed as follows. Figure 1 As shown in Figure d, it can be seen that the microspheres prepared by the collagen-mucopolysaccharide solution with a collagen concentration of 0.8% have a diameter range of 450-650 μm, and some microspheres are agglomerated together; the microspheres prepared by the collagen-mucopolysaccharide solution with a collagen concentration of 1% have a diameter range of 500-650 μm, and exhibit a normal distribution with regular shapes and individual spheres; the microspheres prepared by the collagen-mucopolysaccharide solution with a collagen concentration of 1.5% have a diameter range of 500-900 μm, which is relatively large and has a wide distribution range, and does not meet the expected diameter size.

[0121] The porous microspheres prepared from collagen-mucopolysaccharide solutions with different collagen concentrations were further characterized as follows:

[0122] Porous microspheres prepared from collagen-mucopolysaccharide solutions of different collagen concentrations were either whole or broken off with pointed tweezers and fixed onto a stage with conductive adhesive strips. The stage was placed in the instrument for vacuum platinum spraying for 30 seconds, then removed and placed on the base of a scanning electron microscope. The focus and magnification were adjusted to characterize the surface and internal pores of the microspheres.

[0123] Electron microscopy results as follows Figure 2As shown in Figure a (freezing temperature -23℃), 0.8% CMS represents porous microspheres prepared with a collagen-mucopolysaccharide solution at a concentration of 0.8% collagen, 1% CMS represents porous microspheres prepared with a collagen-mucopolysaccharide solution at a concentration of 1% collagen, and 1.5% CMS represents porous microspheres prepared with a collagen-mucopolysaccharide solution at a concentration of 1.5% collagen. It can be seen that the porous microspheres prepared with a collagen-mucopolysaccharide solution at a concentration of 1% collagen at -23℃ exhibit high porosity on both the surface and interior, which is higher than that of porous microspheres prepared under other conditions.

[0124] 3. Inner diameter of the syringe needle

[0125] Porous microspheres were prepared according to the method described above, except that in step 3, syringe needles with pore inner diameters of 27G and 30G were used to add the microspheres dropwise.

[0126] The results of photographing solid microspheres prepared with syringe needles of different orifice diameters after water dissolution are as follows: Figure 1 As can be seen from the data, when the 27G needle is added dropwise to the oil phase, the resulting microspheres have a large diameter and are irregular; when the 30G needle is added dropwise to the oil phase, the microsphere diameter decreases, and the uniformity is good, with a regular shape.

[0127] 4. Freezing temperature

[0128] Porous microspheres were prepared according to the method described above, except that liquid nitrogen with a freezing temperature of -23℃ or -196℃ was used in step 5, 2).

[0129] Characterization results of porous microspheres obtained at different freezing temperatures are as follows: Figure 2 a (scale bar: 100um), 2b and 2c show that the microspheres prepared by vacuum drying after freezing at -23℃ have large surface and internal pore diameters, and the interconnected structure of internal and external pores provides a medium for the migration of stem cells inside the microspheres. The microspheres prepared by drying after freezing at -196℃ have dense pores and small pore diameters, which cannot meet the pore diameter required for cell migration.

[0130] The porous microspheres prepared at the above different freezing temperatures were either whole or broken off with pointed tweezers and fixed on a stage with conductive adhesive strips. The stage was placed in the instrument for vacuum platinum spraying for 30 seconds and then removed and placed on the base of a scanning electron microscope. The focus and magnification were adjusted to characterize the surface and internal pores of the microspheres.

[0131] A magnified image of the pore size of porous microspheres prepared from a 1% collagen-mucopolysaccharide solution at -23°C using electron microscopy is shown below. Figure 2As shown in b and 2c, porous microspheres prepared from a 1% collagen-mucopolysaccharide solution at -23°C exhibit high porosity on both the surface and interior, with interconnected pores. The outer pores are small, while the inner pores are large, which facilitates the inflow of nutrients and the removal of metabolic products during cell culture. The pore size of the porous microspheres ranges from 20 to 60 μm.

[0132] Therefore, it can be seen that the above-mentioned optimal parameters are all parameters in the preparation method described above.

[0133] Example 2: Obtaining microtissues by in vitro 3D culture of injectable porous microspheres

[0134] Cell sources in the examples:

[0135] Mesenchymal stem cells (MSCs): Cyagen OriCell HUXMA-01001; cells were labeled with green fluorescent protein (GFP) during use (Assessment of the green florescence protein labeling method for trackign implanted mesenchymal stem cells).

[0136] Human immortalized epidermal cell line (HaCaT cells): Cyagen OriCell H5-1001; cells were labeled with green fluorescent protein (GFP) during use (Assessment of the green florescence protein labeling method for trackign implanted mesenchymal stem cells).

[0137] Mouse embryonic fibroblasts (NIH / 3T3 cells): Cyagen M5-0301;

[0138] I. Injectable porous microspheres for in vitro culture of microtissues

[0139] 1. The porous microspheres prepared by the method in Example 1 were dried overnight in a vacuum drying oven at 120°C and then placed in a clean bench for later use.

[0140] 2. Digest P5 passage MSCs, HaCaT cells, or 3T3 cell lines with a confluence of 80%-90% using trypsin.

[0141] 3. Place the porous microspheres from step 1 into a spinner culture flask and add an appropriate amount of cell culture medium to cover the microspheres, allowing the microspheres to fully absorb the culture medium, thus obtaining microspheres containing culture medium.

[0142] 4. The harvested P5 generation MSCs, HaCaT cells, or 3T3 cells are processed at a rate of 2 × 10⁻⁶. 4 The culture medium-containing microspheres obtained in step 3 were inoculated at a concentration of / ml;

[0143] 5. The microspheres containing culture medium and seeded cells obtained in step 4 above were placed in a bioreactor (PFERFFER, CELLSPIN spinner) for 3D dynamic culture. The bioreactor was rotated at 45 rpm / min and the culture conditions were 37°C and 5% CO2 incubator.

[0144] 6. After culturing for different periods, the products are harvested, which are the micro-tissues of each cell.

[0145] 7. Testing

[0146] The micro-tissue samples obtained above were analyzed using inverted fluorescence microscopy, immunofluorescence staining, Masson staining, and crystal violet staining.

[0147] 1) The harvested samples were transferred to a 6cm culture dish, placed under a fluorescence inverted microscope for observation and photographing (excitation wavelength 488nm).

[0148] 2) Immunofluorescence staining: After fixing the harvested samples with 4% paraformaldehyde for 1 hour, excess water was absorbed along the edge of the microspheres with absorbent paper. Using pointed forceps, the samples were lifted along the lower edge of the micro-tissue and placed in a tissue embedding cassette containing embedding medium. The cassette was gently pressed to the bottom and then transferred to -80°C for freezing. Sections were prepared using a cryostat, with a section thickness of 8-10 μm. After washing away the embedding medium with PBS, DAPI staining solution was added to stain the cell nuclei. The sections were then mounted with anti-quenching mounting medium and observed and photographed under a fluorescence microscope.

[0149] 3) Masson staining: After washing away the embedding agent with PBS, the frozen sections were stained with Masson staining kit (Solarbio, G1340) according to the instructions. The collagen scaffold was blue and the cells were red.

[0150] 4) Crystal violet staining: After washing the cultured micro-tissues with PBS, fix the cells with 95% ethanol, cover the micro-tissues with crystal violet staining solution, let stand at room temperature for 10 min, wash away excess dye with distilled water, and take pictures under an optical microscope.

[0151] Microtissue assay results after 2-5 days of in vitro 3D culture of MSCs cells and porous microspheres are as follows: Figure 3 As shown, direct detection using a fluorescence inverted microscope is as follows: Figure 3As shown in Figure a, MSCs spread and grow uniformly on the surface of the microspheres, and the microsphere structure remains intact, indicating that no degradation occurred during in vitro culture. Microtissue staining microscopy examination of MSCs and porous microspheres after 5 days of in vitro 3D culture is shown in Figure a. Figure 3 As shown in Figure b, the left image is an immunofluorescence image, and the right image is a Masson staining image. It shows that MSCs migrate and grow from the surface of the microspheres inwards, forming a tissue-like structure similar to cells and extracellular matrix within the microspheres. This is a micro-tissue obtained from in vitro culture. The right image also shows that the prepared porous microspheres have high porosity and interconnected pores, allowing cells to migrate into the microspheres. The micro-tissue crystal violet staining microscopic examination results of MSCs and porous microspheres after 3 days of in vitro 3D culture are as follows: Figure 3 As shown in Figure c, it can be seen that from 4 hours after MSCs inoculation to day 3, the cells rapidly proliferated on the surface and inside of the microspheres, and the cells were evenly distributed inside the microspheres to form a structure similar to tissue. The high porosity of the microspheres greatly increased the adhesion area required for the massive proliferation of cells.

[0152] Direct microscopic examination of microtissues from epidermal cell line HaCaT cultured in vitro for 3D for 10 days using porous microspheres is as follows: Figure 4 a) Immunofluorescence staining microscopy examination of a cross section of a tissue section containing epidermal cells cultured in microspheres for 10 days, as shown in the figure. Figure 4 As shown in b, it can be seen that after the epidermal cell line is inoculated into porous microspheres and cultured for 10 days, the cells rapidly proliferate on the surface of the microspheres and migrate and grow inward along the pores. The cells form a complete single-cell layer or a multilayered cell structure containing multiple cells on the surface of the microspheres, similar to the epidermal structure of skin tissue, forming a uniformly distributed epidermal-like micro-tissue, which is the epithelial tissue.

[0153] Immunofluorescence staining and microscopic examination of microtissues from NIH / 3T3 fibroblast cell line cultured in vitro for 2 days using porous microspheres are shown below. Figure 4 As shown in Figure c, this is an immunofluorescence staining image of fibroblast cell lines cultured in porous microspheres for 2 days. After being seeded on the surface of porous microspheres for 2 days, the cells rapidly proliferate and migrate into the pores inside the microspheres, forming a uniformly distributed dermal-like micro-tissue, which is connective tissue.

[0154] II. Control of cell culture using commercially available microspheres

[0155] Each of the cells described above was seeded onto Huakan's commercially available gelatin microspheres (Beijing Huakan Biotechnology Co., Ltd., catalog number: WO1-10).

[0156] MSCs direct microscopic detection results are as follows Figure 5As shown in Figure a, the upper image is a bright-field image, and the lower image is a fluorescence image. MSCs adhere and proliferate slowly in commercially available gelatin microspheres. With prolonged in vitro culture, the gelatin microspheres rapidly degrade, releasing cells and forming cell spheroids, which affects the cell expansion rate. In contrast, the porous microspheres of this invention allow MSCs to spread and grow uniformly on the microsphere surface. The microsphere structure remains intact and does not degrade during in vitro culture, thus not affecting the cell expansion rate (e.g., ...). Figure 3 a).

[0157] HaCaT cell microscopic examination results are as follows: Figure 5 As shown in Figure b, the upper image is a bright-field image, and the lower image is a fluorescence image. HaCaT cells in gelatin microspheres have difficulty adhering to the surface of the microspheres; instead, they adhere to each other and form spheres, making it difficult to form an epidermal-like structure. However, the porous microspheres of this invention enable HaCaT cells to form a complete monocellular layer or a multilayered cell structure on the surface of the microspheres, similar to the epidermal structure of skin tissue, forming a uniformly distributed epidermal-like microtissue (e.g., ...). Figure 4 (a and 4b).

[0158] After culturing 3T3 cells in gelatin microspheres, the cell nuclei were stained with DAPI staining solution, and the microscopic examination results are as follows: Figure 5 As shown in c, 3T3 cells can adhere well, proliferate, and be evenly distributed in gelatin microspheres.

[0159] Example 3: Application of MSCs microtissues in promoting wound healing

[0160] 1. Construction of a full-skin injury model on the back (Reference: The mouse excisional woundsplinting model, including applications for stem cell transplantation)

[0161] A full-back skin lesion model was established in 7-8 week old female C57 mice. Using a 5mm skin biopsy device, full-back skin lesions were made along the left and right sides and the top and bottom sides of the mouse's back. Figure 6 a.

[0162] 2. Micro-tissue promotes wound healing

[0163] The MSCs microtissue obtained by culturing MSCs and porous microspheres prepared in Example 1 for 4 days in vitro (a portion of the MSCs microtissue was degraded using enzymatic digestion and cell counting was performed to calculate the average number of cells growing on each microsphere; based on the number of microspheres transplanted into the wound, it was estimated that approximately 50,000 MSCs were transplanted into each wound) was aspirated into a 10ml syringe with the syringe needle pointing upwards, allowing the microtissue to sink to the bottom, draining the supernatant, and retaining the microtissue. The microtissue was then injected into the wound defect on the back of mice with total skin damage, and spread out to completely cover the wound. A 3M transparent wound dressing was carefully applied to the wound and surrounding skin (Note: When applying the 3M transparent dressing, smooth it out from the center outwards to prevent wrinkles) to cover most of the back skin. A self-adhesive bandage was wrapped around the mouse's back towards the abdomen for 2 weeks, starting from the wound. The bandage joint was then sutured with sterile sutures to prevent the bandage from falling off, exposing the wound, causing infection, and affecting the experimental results.

[0164] Following microtissue transplantation into a total skin wound, mice were anesthetized via intraperitoneal injection on days 3, 7, 14, 21, and 40. After anesthesia, the bandages were carefully removed, and the mice were placed prone on a sterile operating table. Skin tissue from the wound and surrounding area was harvested using ophthalmic scissors and pointed forceps. After washing in PBS to remove blood, the tissue was fixed overnight in 4% PFA solution. The fixed skin tissue was washed three times with PBS, 8 hours each time. The washed skin tissue was then dehydrated at gradient concentrations of 10%, 20%, and 30% sucrose, with each concentration dehydrating for 8 hours. After dehydration, the surface moisture of the tissue was absorbed with gauze, and the tissue was trimmed with scissors and forceps. The tissue was then embedded in an embedding cassette containing OCT and frozen at -80°C before being sectioned using a cryostat. The sectioned tissue was stained with hematoxylin and eosin (HE) and eosin (IF) to observe the degradation and release of MSCs from the porous microspheres.

[0165] HE staining results are as follows Figure 6 As shown in b, the dotted circle indicates the undegraded porous microspheres at the wound site. The results show that the porous microspheres can slowly degrade over time, and the area of ​​the dotted part gradually decreases, continuously releasing MSCs and participating in the entire wound healing process to play a therapeutic role.

[0166] IF staining results as follows Figure 6As shown in Figure c, MSC-CMS represents the result of MSC microtissue transplantation into wounds after 4 days of in vitro 3D culture of MSCs and porous microspheres (50,000 transplanted cells / wound). MSC-matri represents the result of transplantation into wounds after mixing 1.5 million MSCs with 20 μL of Matrigel gel (50,000 transplanted cells / wound). CMS represents the result of wound transplantation using collagen-mucopolysaccharide porous microspheres. Control represents the control group without any treatment. White bright spots represent surviving MSCs. The results show that the microtissue obtained by culturing MSCs in porous microspheres can improve the survival rate of MSCs, prolong the survival time of MSCs in vivo, and achieve the same therapeutic effect with a smaller number of cells.

Claims

1. A method for preparing porous microspheres, comprising the following steps: 1) Prepare a biological macromolecule-mucopolysaccharide solution as the aqueous phase and an organic solution containing an emulsifier as the oil phase; The biopolymer-mucopolysaccharide solution is prepared by the following method: a mucopolysaccharide solution is added dropwise to a biopolymer solution and mixed thoroughly to obtain the biopolymer-mucopolysaccharide solution; wherein... The dripping is performed according to a mass ratio of 5-11:1 for the added biopolymer and the mucopolysaccharide. The organic solution containing the emulsifier is obtained by stirring and mixing the emulsifier with an organic solvent. 2) The biopolymer-mucopolysaccharide solution is added dropwise to the organic solution containing the emulsifier, and the mixture is stirred until homogeneous to obtain an oil-water emulsion; 3) The oil-water emulsion is subjected to a crosslinking reaction under the action of a crosslinking agent to obtain a crosslinking reaction product containing solid microspheres; 4) The microspheres in the cross-linking reaction product containing solid microspheres are sequentially frozen and freeze-dried to form a microsphere porous structure, thereby obtaining porous microspheres; The biopolymer is composed of one or more of collagen, alginate, polylactic acid, polyvinyl alcohol, chitosan, and their degradation products. Alternatively, the mucopolysaccharide may be composed of one or more of keratin sulfate, chondroitin sulfate, hyaluronic acid, and dermatan sulfate.

2. The method according to claim 1, characterized in that: The stirring speed for all mixing operations is 50-2000 rpm; Or / and, the addition of the polymer-mucopolysaccharide solution to the organic solution containing the emulsifier is performed dropwise using a syringe needle with an inner diameter of 20-34G; Or / and, the freezing conditions are 0 to -200°C.

3. The method according to claim 2, characterized in that: The concentration of collagen in the collagen-mucopolysaccharide solution is 0.5%-5%; The concentration of collagen in the collagen-mucopolysaccharide solution is 0.8%-1.5%; Or / and, the stirring speed is 500-600 rpm; Or / and, the freezing conditions are -10 to -80°C.

4. Porous microspheres prepared by any one of the methods described in claims 1-3.

5. The porous microspheres according to claim 4, characterized in that: The porous microspheres have at least one of the following properties: A1) Biodegradable properties in vivo; A2) Internal and external pores are connected; A3) Diameter is 100-1500um, and pore size is 8-100um; A4) Injectability.

6. The use of the porous microspheres according to claim 4 or 5 in any of the following: B1) In vitro 3D culture, expansion, migration, or differentiation of cells; B2) Preparation of cellular microtissues; B3) Preparation of transplant therapy products; B4) Prepare small molecule substances or sustained-release products in cells.

7. A cellular microtissue, prepared by a method comprising the steps of: seeding cells on porous microspheres as described in claim 4 or 5 and culturing them in vitro in 3D to obtain the cellular microtissue.

8. The use of the cellular microtissue described in claim 7 in the preparation of transplantation therapy products.

9. The application according to claim 6 or 8, characterized in that: The transplant treatment product is an injectable or topical product.

10. The application according to claim 9, characterized in that: The transplantation treatment product is used to treat diseases caused by wound damage, joint damage, endometritis, or for cosmetic surgery.

11. The application according to claim 6 or the cell microtissue according to claim 7, characterized in that: The cells are cultured animal or human cells; The cellular microtissues include epithelial tissue, connective tissue, muscle tissue, or nerve tissue.

Citation Information

Patent Citations

  • Dual-hole polysaccharide microspheres, preparation method and purpose thereof

    CN103341172A

  • Porous polymer microsphere for the prevention or treatment of bone diseases or cartilage diseases, and preparation method thereof

    KR1020190035051A